91 – 100 of 146
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
(
- Contribution to journal › Article